Cargando…
Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
BACKGROUND: The subclinical pathophysiology of proliferative lupus nephritis (PLN) has not been fully elucidated. Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is associated with PLN, but prediagnostic levels have not been reported. METHODS: We performed a retrospective case-contro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757094/ https://www.ncbi.nlm.nih.gov/pubmed/29435367 http://dx.doi.org/10.1155/2017/1872846 |
_version_ | 1783290801421287424 |
---|---|
author | Olson, S. W. Lee, J. J. Poirier, M. Little, D. J. Prince, L. K. Baker, T. P. Edison, J. D. Abbott, K. C. |
author_facet | Olson, S. W. Lee, J. J. Poirier, M. Little, D. J. Prince, L. K. Baker, T. P. Edison, J. D. Abbott, K. C. |
author_sort | Olson, S. W. |
collection | PubMed |
description | BACKGROUND: The subclinical pathophysiology of proliferative lupus nephritis (PLN) has not been fully elucidated. Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is associated with PLN, but prediagnostic levels have not been reported. METHODS: We performed a retrospective case-control Department of Defense Serum Repository (DoDSR) study comparing MPO-ANCA levels in longitudinal prediagnostic serum samples for 23 biopsy confirmed proliferative lupus nephritis (PLN) patients to DoDSR identified age, sex, race, and age of serum matched healthy and SLE without LN disease controls. We also compared the temporal relationship of MPO-ANCA to anti-double stranded DNA antibodies (dsDNAab). RESULTS: A greater proportion of PLN patients had prediagnostic MPO-ANCA levels above ≥3 U/mL and ≥6 U/mL compared to SLE without LN (91% versus 43%, p < 0.001; 57% versus 5%, p < 0.001, resp.). In subgroup analysis, the MPO-ANCA threshold of ≥3 U/mL was significant at <1 year (88% versus 39%, p = 0.007) and 1–4 years (87% versus 38%, p = 0.009) prior to diagnosis. Statistically significant subclinical MPO-ANCA levels (≥3 U/mL) occurred prior to statistically significant dsDNAab ≥ 3 IU/ml (89% versus 11%, p = 0.003). CONCLUSIONS: Subclinical MPO-ANCA levels could distinguish future PLN from SLE without LN. MPO-ANCA manifests prior to clinical disease and subclinical dsDNAab to suggest that it may contribute directly to PLN pathogenicity. |
format | Online Article Text |
id | pubmed-5757094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-57570942018-02-12 Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis Olson, S. W. Lee, J. J. Poirier, M. Little, D. J. Prince, L. K. Baker, T. P. Edison, J. D. Abbott, K. C. Autoimmune Dis Research Article BACKGROUND: The subclinical pathophysiology of proliferative lupus nephritis (PLN) has not been fully elucidated. Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is associated with PLN, but prediagnostic levels have not been reported. METHODS: We performed a retrospective case-control Department of Defense Serum Repository (DoDSR) study comparing MPO-ANCA levels in longitudinal prediagnostic serum samples for 23 biopsy confirmed proliferative lupus nephritis (PLN) patients to DoDSR identified age, sex, race, and age of serum matched healthy and SLE without LN disease controls. We also compared the temporal relationship of MPO-ANCA to anti-double stranded DNA antibodies (dsDNAab). RESULTS: A greater proportion of PLN patients had prediagnostic MPO-ANCA levels above ≥3 U/mL and ≥6 U/mL compared to SLE without LN (91% versus 43%, p < 0.001; 57% versus 5%, p < 0.001, resp.). In subgroup analysis, the MPO-ANCA threshold of ≥3 U/mL was significant at <1 year (88% versus 39%, p = 0.007) and 1–4 years (87% versus 38%, p = 0.009) prior to diagnosis. Statistically significant subclinical MPO-ANCA levels (≥3 U/mL) occurred prior to statistically significant dsDNAab ≥ 3 IU/ml (89% versus 11%, p = 0.003). CONCLUSIONS: Subclinical MPO-ANCA levels could distinguish future PLN from SLE without LN. MPO-ANCA manifests prior to clinical disease and subclinical dsDNAab to suggest that it may contribute directly to PLN pathogenicity. Hindawi 2017 2017-12-24 /pmc/articles/PMC5757094/ /pubmed/29435367 http://dx.doi.org/10.1155/2017/1872846 Text en Copyright © 2017 S. W. Olson et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Olson, S. W. Lee, J. J. Poirier, M. Little, D. J. Prince, L. K. Baker, T. P. Edison, J. D. Abbott, K. C. Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis |
title | Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis |
title_full | Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis |
title_fullStr | Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis |
title_full_unstemmed | Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis |
title_short | Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis |
title_sort | anti-myeloperoxidase antibodies associate with future proliferative lupus nephritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757094/ https://www.ncbi.nlm.nih.gov/pubmed/29435367 http://dx.doi.org/10.1155/2017/1872846 |
work_keys_str_mv | AT olsonsw antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis AT leejj antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis AT poirierm antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis AT littledj antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis AT princelk antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis AT bakertp antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis AT edisonjd antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis AT abbottkc antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis |